Enovis Corporation (ENOV) 12-Month Stock Forecast & Price Target Cone

ENOV scores 44 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC of -32.7% and FCF yield of 1.51%); Whale 13F Flow at 12/20 (institutional accumulation and options positioning); Insider Conviction at 8/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (beta of 1.0 and sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z of 0.2, Piotroski F of 7/9, Debt/Equity of 0.85).

For a prospective investor, the weakest pillars are the cash engine and insider conviction, while institutional positioning is the relative bright spot. The low ROIC and Altman Z-Score point to a business that has not yet converted capital into returns and sits in a financially stressed zone. The Piotroski score of 7/9 suggests some internal financial-quality signals remain intact, which partially offsets the distress readings.

Enovis Corporation is listed on the NYSE and classified under the Health Care sector, within the Industrial Specialties industry,. Per the market data, the company reports a gross margin of 59.8%, but the source does not explain the underlying business activities that generate it.

Revenue rose from $1.71B in FY 2023 to $2.25B in FY 2025, while operating losses widened from -$65.7M to -$1.12B over the same span. Market data reports an operating margin of -50% and a net margin of -52.7%. ROIC is -32.7%, the Altman Z-Score is 0.2, and the Piotroski F-Score is 7/9. Debt/Equity is 0.85 per the same rating, and cash of $36.4M sits against debt of $1.26B in FY 2025.

• 🐂 Primary Bull Case: Institutional accumulation and options positioning (12/20 whale pillar) and a Piotroski F-Score of 7/9 suggest some financial-quality and sponsorship support beneath the distressed headline metrics. With Fundamental Cash Engine at 8/20 (ROIC -32.7%, FCF yield 1.51%) and Institutional Whale Flow at 7/20, sustained execution supports upside toward the top of the $16.70 – $32.41 52-week range.
• 🐻 Primary Bear Case: ROIC of -32.7%, an Altman Z-Score of 0.2, and operating losses widening to -$1.12B against $1.26B of debt point to a financially stressed business with weak cash returns. Investors must weigh current valuation against -50.0% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only related signal in the feed is the acquisition-related price target cut and the M&A overhang referenced in headlines, which an investor may wish to track for ripple effects on leverage and capital allocation, though the source does not quantify these.

• Key Question #1: What products and services generate the $2.25B in FY 2025 revenue, and what drove the operating loss?
• Key Question #2: What acquisition is referenced in the UBS price target cut and the M&A overhang headlines, and how is it financed?
• Key Question #3: How does the company plan to cover $1.26B of debt against $36.4M of cash, and what is the maturity profile?